Skip to main content
. 2021 Aug 11;27(19):5317–5324. doi: 10.1158/1078-0432.CCR-21-1239

Table 2.

Multivariate analysis of HER2, clinicopathological, and treatment variables with IBE as endpoint.

Univariate Multivariate
Variable Subgroup n HR (95% CI) P HR (95% CI) P
HER2 Negative 398 1 (reference) 1 (reference)
Positive (IHC 3+) 214 2.03 (1.45–2.86) <0.0001 1.92 (1.33–2.76) 0.0004
Age Years (mean) 57.4 0.99 (0.96–1.02) 0.42 0.98 (0.95–1.01) 0.27
Excision Complete 415 1 (reference) 1 (reference)
Uncertain 100 1.49 (0.96–2.31) 0.074 1.65 (1.06–2.56) 0.027
Incomplete 97 1.68 (1.09–2.58) 0.019 1.94 (1.25–3.02) 0.0031
Trend test 0.0095 0.0012
Size mm (mean) 15.7 1.03 (1.02–1.05) 0.0002 1.02 (1.01–1.04) 0.012
Grade Low 34 1 (reference) 1 (reference)
Intermediate 102 1.43 (0.48–4.25) 0.52 0.89 (0.28–2.83) 0.84
High 476 2.15 (0.79–5.84) 0.13 1.01 (0.32–3.22) 0.99
Trend test 0.036 0.74
Necrosis No 45 1 (reference) 1 (reference)
Yes 567 1.85 (0.81–4.19) 0.14 1.17 (0.45–3.05) 0.75
Inflammation No 123 1 (reference) 1 (reference)
Yes 489 1.96 (1.16–3.31) 0.011 1.39 (0.77–2.50) 0.27
Radiotherapy No 388 1 (reference) 1 (reference)
Yes 224 0.33 (0.21–0.51) <0.0001 0.30 (0.19–0.47) <0.0001
Tamoxifen No 288 1 (reference) 1 (reference)
Yes 324 0.65 (0.46–0.92) 0.015 0.71 (0.50–1.01) 0.056

Note: Endpoint: IBE; n = 612; events = 133; univariate analyses restricted to the same sample size as available for multivariate analyses.